OPKO Health, First Quarter
Digest more
Grants OPKO a 15% equity interest in NicoyaMIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has ...
ModeX pipeline progress, 4Kscore reimbursement catalysts, Q2 revenue guidance, cash/buybacks—read key takeaways.
Zacks Investment Research on MSN
Here's why you should hold OPK stock in your portfolio for now
OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism ...
Fintel on MSN
Barrington Research downgrades OPKO Health (OPK)
Fintel reports that on April 29, 2026, Barrington Research downgraded their outlook for OPKO Health (NasdaqGS:OPK) from ...
Opko Health Inc. (OPK) on Tuesday reported a loss of $54.8 million in its first quarter. The Miami-based company said it had a loss of 7 cents per share. The results met Wall Street expectations. The ...
24d
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19 ...
Opko enters into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx). Opko says the purchase agreement is secured by its profit share payments from Pfizer received ...
The U.S. Food and Drug Administration didn't approve human growth hormone somatrogon. The agency's decision came as a surprise since somatrogon has won approvals in other countries. The FDA's decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results